Update on eVOLVE-Lung02 Phase III Trial of Volrustomig Plus Chemotherapy in Metastatic Non-Small Cell Lung Cancer

AstraZeneca Ends Phase 3 Volrustomig Study in Lung Cancer After Interim Review Signals Low Likelihood of Success

As reported on BioSpace, AstraZeneca has discontinued a pivotal Phase 3 trial evaluating its investigational bispecific antibody volrustomig in advanced non-small cell lung cancer (NSCLC) after an interim analysis indicated the study was unlikely to meet its primary objectives. The eVOLVE-Lung02 trial was assessing volrustomig in combination with chemotherapy as a first-line treatment for patients […]

Another disappointment: AstraZeneca halts Phase III lung cancer trial for volrustomig - European Biotechnology Magazine

AstraZeneca has discontinued a pivotal Phase III trial of its dual checkpoint inhibitor volrustomig in metastatic non-small cell lung cancer (NSCLC), after an independent committee concluded that the study was unlikely to meet its primary endpoints. The setback comes as the company faces growing pressure to deliver new oncology products. The post Another disappointment: AstraZeneca halts Phase III lung cancer trial for volrustomig appeared first…

Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer

AstraZeneca is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig in combination with chemotherapy as a 1st-line therapy compared to pembrolizumab and chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC) whose tumours express PD-L1 less than 50%. - - This decision is based on the recommendation of the Independent Data Monitoring Committee (IDMC) following a planned review of trial data. The IDMC conclu…

eVOLVE-Lung02 Trial of Volrustomig Discontinued in Metastatic NSCLC

The phase 3 eVOLVE-Lung02 trial will halt after an independent committee concluded that volrustomig plus chemotherapy was unlikely to improve survival.